Genomic Health, Inc. (NASDAQ: GHDX) closed to $30.93. Recent traded volume was 194,150 shares versus to it an average volume of 1.093B shares. The stock’s day range was recorded between a low of $26.54 and a high $37.50. The one year high of the company is $26.54 and the one year low is $32.02.
Genomic Health, Inc. (GHDX) recently stated financial results and business progress for the quarter and year ended December 31, 2017.
Total revenue was $340.8M in the full year 2017, contrast with $327.9M in 2016, an raise of 4 percent.
U.S. product revenue was $287.4M in the full year 2017, contrast with $280.1M in the full year 2016, an raise of 3 percent. U.S. invasive breast revenue from Oncotype DX Breast Recurrence Score® tests was $259.7M in the full year 2017, contrast with $257.0M in the full year 2016. U.S. prostate test revenue from Oncotype DX® Genomic Prostate Score™ (GPS™) tests was $17.9M in the full year 2017, contrast with $10.8M in the full year 2016, an raise of 66 percent.
International revenue for the full year 2017 was $53.1M contrast with $46.8M in 2016, an raise of 13 percent, and an raise of 15 percent on a non-GAAP constant currency basis.
Operating loss improved to $6.5M for the year ended December 31, 2017, contrast with $15.4M for the year ended December 31, 2016. Net loss was $3.9M, or $0.11 per share on a basic and diluted basis, for the year ended December 31, 2017, contrast with a net loss of $13.9M, or $0.42 per share on a basic and diluted basis, for the year ended December 31, 2016.
2018 Financial Outlook
In positioning its business to deliver near-term growth and raised profitability, the company is directing its focus and resource allocation toward catalysts that it expects will drive further adoption and reimbursement of its portfolio globally with greater operational efficiency. Specifically, the company plans to direct resources to expand its Oncotype DX offering through the development of in vitro diagnostic (IVD) test solutions, including on the Biocartis® Idylla™ platform, to raise global access in markets where localized testing is critical for adoption and reimbursement. With this shift in focus, the company will no longer provide the Oncotype SEQ® Liquid Select™ test or further invest in non-proprietary next-generation sequencing (NGS)-based panels. Accordingly, the company will reduce positions by about 10 percent and take a charge of about $10M in the first quarter for costs associated with personnel reductions and the write-off of certain assets associated with NGS-based panels.
(GHDX) price volatility for a month noted as 3.60% however its price volatility for a week documented as 3.82%. The corporation holds 36.57 million outstanding shares and its 34.41 million shares were floated in the market. The stock established a positive trend of 1.48% in last week and indicated fall of -1.84% in previous month.
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
